Publications
Learn about the research supporting our preclinical and clinical development programs.

Publications

Learn about the research supporting our preclinical and clinical development programs.

Presentations

October 11, 2019
World ADC Congress 2019

BT5528, an EphA2-targeting Bicycle® Toxin Conjugate

September 28, 2019
The European Society of Medical Oncology 2019 Annual Congress

Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumors

May 2, 2019
30th Symposium on Medicinal Chemistry

Bicycles® – An entirely new class of therapeutics

April 25, 2019
6th Annual Peptides Congress

Activation of CD137 using multivalent and tumour targeted bicyclic peptides

April 3, 2019
ELRIG Research & Innovation

Bicycles® – An entirely new class of therapeutics

April 2, 2019
AACR

Activation of 4-1BB using multivalent and tumour targeted bicyclic peptides

April 2, 2019
AACR

BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models

April 2, 2019
AARC

BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models

March 6, 2019
9th Annual World ADC Conference

BT5528: A Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumours

November 13, 2018
EORTC

Preliminary pharmacokinetic assessment of BT1718: Aphase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) in patients with advanced solid tumours

November 13, 2018
EORTC

BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): profound efficacy without bleeding and coagulation abnormalities in animal models

November 12, 2018
PEGS

Novel Multimers of Bicyclic Peptides Cluster and Activate CD137 (4-1BB): A Costimulatory T -Cell Checkpoint Receptor

November 6, 2018
SITC

Activation of the T cell costimulatory protein CD137 using multivalent bicyclic peptides

October 9, 2018
ELRIG Drug Discovery

Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137

October 9, 2018
ELRIG Drug Discovery

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

October 1, 2018
NCRI

A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumours

August 31, 2018
35th European Peptide Symposium

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

July 18, 2018
Promega Biologics

Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137

June 5, 2018
ASCO

A Cancer Research UK phase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumours

April 14, 2018
AACR

Bicycle Toxin Conjugates (BTCs) targeting EphA2 for the treatment of solid tumours: Discovery and selection of BT5528

April 14, 2018
AACR

BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2 has potent anti-tumour activity without bleeding or coagulation abnormalities in animal models

April 14, 2018
AACR

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

April 30, 2017
PEGS

Bicyclic Peptides for Positron Emission Tomography (PET) Imaging of MT1-MMP Expressing tumours

April 30, 2017
PEGS

The Bicycle platform: an efficient technology to generate high affinity, high selectivity molecules (Bicycles®) with unique drug like properties that are amenable to conjugation

April 30, 2017
PEGS

Discovery and development of BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumours: In vitro and in vivo activities

April 30, 2017
PEGS

BT1718, a novel Bicycle Drug Conjugate® shows potent anti-tumor activity in diverse cell-derived and patient-derived tumor xenograft models

April 30, 2017
PEGS

Identification of high affinity, highly selective bicyclic peptides (Bicycles®) to transmembrane proteins using phage display screening on whole cells

April 1, 2017
AACR

BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumours: Design of bicyclic peptide and linker selection

April 1, 2017
AACR

Bicyclic Peptides for Positron Emission Tomography (PET) Imaging of MT1-MMP Expressing Tumors

April 1, 2017
AACR

Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer